Compounds > sw033291
Page last updated: 2024-12-10

sw033291

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SW033291: inhibits 15-hydroxyprostaglandin dehydrogenase (15-PGDH) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3337839
CHEMBL ID4061483
SCHEMBL ID15525569
MeSH IDM000607500

Synonyms (38)

Synonym
HMS1481P18
EU-0011111
CHEMDIV3_003164 ,
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[2,3-b]pyridin-3-amine
AKOS001635848
S7900
CS-4513
SCHEMBL15525569
HY-16968
AC-32909
sw033291
SR-01000489258-1
sr-01000489258
459147-39-8
mfcd02973087
EX-A632
sw-033291
2-(butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
sw 033291
2-(butylsulfinyl)-4-phenyl-6-(2-thienyl)-thieno[2,3-b]pyridin-3-amine
AS-72360
sw033291, >=98% (hplc)
2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
sw-033291;sw 033291
BCP15631
FT-0700311
us9789116, sw033291
bdbm347359
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[5,4-b]pyridin-3-amine
EN300-246041
SB19146
CHEMBL4061483 ,
CCG-268797
bdbm50266252
nsc-787269
nsc787269
2-(butylsulfinyl)-4-phenyl-6-(2-thienyl)-thieno[2,3-b]pyridine-3-amine
Z2213885911
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)IC50 (µMol)0.00220.00220.57502.7000AID1482373
15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)Ki0.00010.00010.00010.0001AID1482410; AID1918561
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
kidney development15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
prostaglandin metabolic process15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
transforming growth factor beta receptor signaling pathway15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
female pregnancy15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
parturition15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
lipoxygenase pathway15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
ovulation15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
response to estradiol15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
response to lipopolysaccharide15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
positive regulation of apoptotic process15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
response to ethanol15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
negative regulation of cell cycle15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
thrombin-activated receptor signaling pathway15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
ductus arteriosus closure15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
regulation of prostaglandin catabolic process15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
prostaglandin E receptor activity15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
identical protein binding15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
NAD binding15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
NAD+ binding15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleoplasm15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
cytosol15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
basolateral plasma membrane15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
extracellular exosome15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
cytoplasm15-hydroxyprostaglandin dehydrogenase [NAD(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1482384Plasma concentration in CD1 mouse at 10 mg/kg, ip measured at 3 hrs post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482382Cmax in CD1 mouse at 10 mg/kg, ip measured at 10 to 1440 mins post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482375Inhibition of 15-PGDH in human A549 cells assessed as increase in IL-1beta-stimulated PGE2 levels at 2500 nM after 8 hrs by ELISA relative to DMSO2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482374Inhibition of 15-PGDH in human A549 cells assessed as increase in IL-1beta-stimulated PGE2 levels at 20 nM after 8 hrs by ELISA relative to DMSO2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1918561Binding affinity to 15-PGDH (unknown origin) assessed as inhibition constant2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
AID1482373Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NAD(+) by fluorescence assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482410Inhibition of 15-PGDH (unknown origin) using PGE2 as substrate preincubated for 12 hrs followed by dialysis for 12 hrs and subsequent addition of NAD+ measured after 12 hrs2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482379Half life in mouse liver S9 fractions at 2 uM in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482383AUC in CD1 mouse at 10 mg/kg, ip measured at 10 to 1440 mins post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482381Protein binding in mouse plasma2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1482377Aqueous solubility of compound in pH 7 citrate buffer using amorphous form after 16 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
AID1918539Antifibrotic activity against bone marrow transplanted mouse model assessed as acceleration in peripheral blood neutrophils recovery at 5 mg/kg,ip bid measured by flow cytometry after 10 days post-transplant recovery period2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (31.25)24.3611
2020's11 (68.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.53 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.58 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.2110naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		3.6270mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
bdp 12
1-(quinoxalin-6-ylcarbonyl)piperidine: modulates AMPA receptor desensitization ; an analog of 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine		2.4110N-acylpiperidine
Bardoxolone
[no description available]		2.4110cyclohexenones
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		3.560prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
leukotriene b4
Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.		2.610dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
12-hydroxy-5,8,10-heptadecatrienoic acid
12-hydroxy-5,8,10-heptadecatrienoic acid: metabolite of arachidonic acid in blood platelet suspension; RN given refers to cpd without isomeric designation		2.610hydroxy polyunsaturated fatty acid;
long-chain fatty acid;
trienoic fatty acid		metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Colitis Gravis
[description not available]		02.4110
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		02.4110
Injury, Ischemia-Reperfusion
[description not available]		02.4110
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		07.4110
Cancer of Colon
[description not available]		02.4110
Cancer of Liver
[description not available]		02.4110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.4110
Cirrhosis
[description not available]		03.5240
Cardiac Failure
[description not available]		03.5240
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		03.5240
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		03.5240
Sarcopenia
Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.		02.610
Cryptogenic Fibrosing Alveolitis
[description not available]		02.6620
Idiopathic Pulmonary Fibrosis
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.		02.6620
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6320
Innate Inflammatory Response
[description not available]		02.2510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Age-Related Osteoporosis
[description not available]		02.2110
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.2110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.1110